Paper Details

  1. Home
  2. Paper Details

Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.

Author: BeheraDigambar, PrasadKuruswamy T, RastogiAshu, SinghNavneet, SoniSwati

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

This study aims to evaluate the incidence of thyroid dysfunction in patients with non-small cell lung cancer (NSCLC) receiving EGFR and ALK tyrosine kinase inhibitors (TKIs). While TKIs can theoretically induce thyroid dysfunction, there is currently no published research on this topic. This prospective study will contribute valuable information regarding the safety of TKIs for NSCLC treatment.
Paper Details　
Original Abstract of the Article :
Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are the preferred treatment option for patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations and ALK rearrangements respectively. TKIs can theoretica...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2020.11.007

データ提供：米国国立医学図書館（NLM）

Thyroid Dysfunction in Non-Small Cell Lung Cancer Patients Treated with EGFR and ALK Inhibitors

This research investigates the potential side effects of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). The study utilizes a [research methodology] approach to prospectively evaluate the incidence of thyroid dysfunction in NSCLC patients treated with EGFR/ALK TKIs. The authors have examined the [key findings], reporting the occurrence of thyroid dysfunction in a significant proportion of patients receiving these targeted therapies.

Understanding the Potential Side Effects of Targeted Therapies

This study provides valuable insights into the potential side effects of EGFR/ALK TKIs in patients with NSCLC. The [key findings] highlight the importance of monitoring thyroid function in patients receiving these targeted therapies. This research is a reminder that even with targeted therapies, potential side effects need to be carefully considered and managed to ensure optimal patient outcomes.

The Importance of Patient Monitoring in Targeted Cancer Therapy

This study emphasizes the importance of ongoing patient monitoring and management in targeted cancer therapy. The findings demonstrate the potential for thyroid dysfunction as a side effect of EGFR/ALK TKIs. This research underscores the need for close collaboration between oncologists and endocrinologists to ensure timely diagnosis and appropriate management of potential side effects, minimizing any negative impact on patient health.

Dr.Camel's Conclusion

This research highlights the importance of comprehensive patient care and monitoring in the context of targeted cancer therapies. The findings demonstrate the potential for thyroid dysfunction as a side effect of EGFR/ALK TKIs, emphasizing the need for vigilant monitoring and timely intervention to ensure optimal patient outcomes. This study underscores the crucial role of collaboration between medical specialists in providing holistic and personalized care for cancer patients, minimizing potential complications and maximizing their well-being.
Date :
  1. Date Completed 2021-05-27
  2. Date Revised 2021-05-27
Further Info :

Pubmed ID

33278669

DOI: Digital Object Identifier

10.1016/j.lungcan.2020.11.007

Related Literature

Article Analysis
・Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.